October 7, 2014
The introduction of cost-effective assessments for the reimbursement of new drugs and medical devices could hobble patient access to innovative medicines, Chugai Pharmaceutical CEO Osamu Nagayama warns. The Japanese government’s plan to adopt such assessments could deal a blow to...read more